Mersana Therapeutics (MRSN) News Today $2.22 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period What is Leerink Partnrs' Forecast for MRSN FY2024 Earnings?November 20 at 2:07 AM | americanbankingnews.comWedbush Lifts Earnings Estimates for Mersana TherapeuticsNovember 18 at 1:51 AM | americanbankingnews.comLeerink Partnrs Issues Optimistic Estimate for MRSN EarningsMersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Equities research analysts at Leerink Partnrs upped their FY2024 EPS estimates for Mersana Therapeutics in a research note issued on Wednesday, November 13th. Leerink Partnrs analyst J. Chang now anticipates that the company will earn ($0.5November 18 at 1:49 AM | marketbeat.comWedbush Predicts Stronger Earnings for Mersana TherapeuticsMersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Analysts at Wedbush increased their FY2024 earnings estimates for Mersana Therapeutics in a report issued on Wednesday, November 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.66) per share forNovember 18 at 1:49 AM | marketbeat.comBuy Rating for Mersana Therapeutics: Anticipated XMT-1660 Data as Key CatalystNovember 15, 2024 | markets.businessinsider.comMersana Therapeutics transferred with Buy rating at CitiNovember 15, 2024 | markets.businessinsider.comMersana Therapeutics (NASDAQ:MRSN) Coverage Initiated by Analysts at CitigroupCitigroup began coverage on shares of Mersana Therapeutics in a research note on Friday. They issued a "buy" rating and a $5.00 price objective on the stock.November 15, 2024 | marketbeat.comMersana Therapeutics Provides Business Update and Financial Results for Third Quarter 2024November 15, 2024 | americanbankingnews.comMersana Therapeutics Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Mersana Therapeutics (MRSN)November 15, 2024 | markets.businessinsider.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deMersana Therapeutics Shares Climb 23% After 3Q Results Beat EstimatesNovember 13, 2024 | marketwatch.comThis Particular Biotech Stock Is Soaring On Two Key AnnouncementsNovember 13, 2024 | theglobeandmail.comMersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comMersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial ResultsNovember 13, 2024 | globenewswire.comMersana Therapeutics (MRSN) Set to Release Earnings on WednesdayNovember 12, 2024 | americanbankingnews.comBrokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Target Price at $6.00November 11, 2024 | americanbankingnews.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, five have given a buy rating andNovember 8, 2024 | marketbeat.comMersana Therapeutics (MRSN) to Release Earnings on WednesdayMersana Therapeutics (NASDAQ:MRSN) will be releasing earnings before the market opens on Wednesday, November 13, Zacks reports.November 7, 2024 | marketbeat.comMersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024November 6, 2024 | globenewswire.comSILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics IncOctober 15, 2024 | finance.yahoo.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Average Recommendation of "Moderate Buy" from BrokeragesMersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight research firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, five have assigned a buy rOctober 14, 2024 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) SVP Alejandra Carvajal Sells 5,598 SharesOctober 8, 2024 | insidertrades.comMersana Therapeutics, Inc. (NASDAQ:MRSN) CFO Sells $16,178.00 in StockOctober 8, 2024 | insidertrades.comMersana Therapeutics (NASDAQ:MRSN) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comBuy Rating on Mersana Therapeutics: Anticipated Upside from XMT-1660 Development and Market Valuation DisconnectOctober 1, 2024 | markets.businessinsider.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Sold by Acadian Asset Management LLCAcadian Asset Management LLC cut its holdings in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 84.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 71,506 shares of the company's stock after sellSeptember 21, 2024 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Given Average Rating of "Moderate Buy" by BrokeragesMersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, fSeptember 19, 2024 | marketbeat.comShort Interest in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Grows By 21.1%Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) was the recipient of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 10,280,000 shares, a growth of 21.1% from the August 15th total of 8,490,000 shares. Based on an average daily volume of 1,220,000 shares, the days-to-cover ratio is currently 8.4 days.September 15, 2024 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) CEO Sells $88,744.48 in StockSeptember 14, 2024 | insidertrades.comBuy Rating for Mersana Therapeutics: Promising ADC Developments and Strategic Market PositioningSeptember 14, 2024 | markets.businessinsider.comMersana Therapeutics, Inc. (NASDAQ:MRSN) CEO Martin H. Jr. Huber Sells 50,423 SharesMersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) CEO Martin H. Jr. Huber sold 50,423 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $1.76, for a total value of $88,744.48. Following the completion of the sale, the chief executive officer now owns 116,327 shares in the company, valued at $204,735.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.September 13, 2024 | marketbeat.comTruist Financial Releases a Buy Rating on Mersana Therapeutics (MRSN)September 11, 2024 | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)September 5, 2024 | markets.businessinsider.comMersana Therapeutics (NASDAQ:MRSN) Given New $5.00 Price Target at CitigroupCitigroup reduced their target price on Mersana Therapeutics from $6.00 to $5.00 and set a "buy" rating on the stock in a research note on Tuesday.August 27, 2024 | marketbeat.comMersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight analysts that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating, five have issuedAugust 25, 2024 | marketbeat.comQ3 2024 EPS Estimates for Mersana Therapeutics, Inc. Decreased by Analyst (NASDAQ:MRSN)Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) - Equities researchers at Leerink Partnrs decreased their Q3 2024 earnings estimates for Mersana Therapeutics in a research report issued to clients and investors on Tuesday, August 13th. Leerink Partnrs analyst J. Chang now expects that theAugust 15, 2024 | marketbeat.comMersana Therapeutics (NASDAQ:MRSN) Releases Earnings Results, Misses Estimates By $0.02 EPSMersana Therapeutics (NASDAQ:MRSN - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). Mersana Therapeutics had a negative return on equity of 260.65% and a negative net margin of 352.01%. The firm had revenue of $2.30 million for the quarter, compared to analyst estimates of $8.72 million. During the same quarter in the previous year, the firm posted ($0.47) EPS. The business's revenue for the quarter was down 78.3% on a year-over-year basis.August 14, 2024 | marketbeat.comBuy Rating on Mersana Therapeutics: Advancing XMT-1660 Program and Promising Tolerability ProfileAugust 14, 2024 | markets.businessinsider.comMersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial ResultsAugust 14, 2024 | finanznachrichten.deMersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | msn.comMersana Therapeutics (NASDAQ:MRSN) Price Target Cut to $3.00 by Analysts at Robert W. BairdRobert W. Baird cut their target price on shares of Mersana Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a report on Wednesday.August 14, 2024 | marketbeat.comMersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial ResultsAugust 13, 2024 | finance.yahoo.comMersana Therapeutics, Inc. (MRSN) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | seekingalpha.comMersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial ResultsAugust 13, 2024 | globenewswire.comMersana Therapeutics is about to announce its earnings — here's what Wall Street expectsAugust 13, 2024 | markets.businessinsider.comMersana Therapeutics (MRSN) Scheduled to Post Earnings on TuesdayMersana Therapeutics (NASDAQ:MRSN) will be releasing earnings before the market opens on Tuesday, August 13, Zacks reports.August 7, 2024 | marketbeat.comMersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024August 6, 2024 | globenewswire.comMersana Therapeutics (NASDAQ:MRSN) shareholders have endured a 83% loss from investing in the stock three years agoAugust 1, 2024 | finance.yahoo.com Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. MRSN Media Mentions By Week MRSN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRSN News Sentiment▼0.560.46▲Average Medical News Sentiment MRSN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRSN Articles This Week▼182▲MRSN Articles Average Week Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARCT News Today AVDL News Today ZYME News Today SEPN News Today COGT News Today BCAX News Today BCYC News Today PAHC News Today COLL News Today IMTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRSN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide vic...Wide Moat Research | SponsoredThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of ...WealthPress | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRSN Stock Alerts